2-47463053-TA-TAA
Variant summary
Our verdict is Pathogenic. The variant received 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_000251.3(MSH2):c.1413dupA(p.Pro472ThrfsTer4) variant causes a frameshift change involving the alteration of a non-conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. Variant has been reported in ClinVar as Pathogenic (★★). Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_000251.3 frameshift
Scores
Clinical Significance
Conservation
Publications
- Lynch syndromeInheritance: AD Classification: DEFINITIVE, SUPPORTIVE Submitted by: G2P, ClinGen, Orphanet
- Lynch syndrome 1Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: Labcorp Genetics (formerly Invitae), Genomics England PanelApp, Ambry Genetics
- Muir-Torre syndromeInheritance: AD Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Genomics England PanelApp, Orphanet, G2P
- mismatch repair cancer syndrome 1Inheritance: AR Classification: DEFINITIVE, SUPPORTIVE Submitted by: ClinGen, Orphanet
- mismatch repair cancer syndrome 2Inheritance: AR Classification: DEFINITIVE, STRONG Submitted by: Labcorp Genetics (formerly Invitae), G2P
- ovarian cancerInheritance: AD Classification: STRONG Submitted by: Genomics England PanelApp
- malignant pancreatic neoplasmInheritance: AD Classification: MODERATE Submitted by: Genomics England PanelApp
- prostate cancerInheritance: AD Classification: MODERATE Submitted by: Ambry Genetics
- rhabdomyosarcomaInheritance: AR Classification: MODERATE Submitted by: Genomics England PanelApp
- breast cancerInheritance: AD Classification: NO_KNOWN Submitted by: Ambry Genetics
- hereditary breast carcinomaInheritance: AD Classification: NO_KNOWN Submitted by: ClinGen
Genome browser will be placed here
ACMG classification
Our verdict: Pathogenic. The variant received 18 ACMG points.
Variant Effect in Transcripts
ACMG analysis was done for transcript: NM_000251.3. You can select a different transcript below to see updated ACMG assignments.
RefSeq Transcripts
| Selected | Gene | Transcript | Tags | HGVSc | HGVSp | Effect | Exon Rank | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|---|
| MSH2 | NM_000251.3 | MANE Select | c.1413dupA | p.Pro472ThrfsTer4 | frameshift | Exon 9 of 16 | NP_000242.1 | ||
| MSH2 | NM_001406674.1 | c.1413dupA | p.Pro472ThrfsTer4 | frameshift | Exon 9 of 18 | NP_001393603.1 | |||
| MSH2 | NM_001406631.1 | c.1413dupA | p.Pro472ThrfsTer4 | frameshift | Exon 9 of 18 | NP_001393560.1 |
Ensembl Transcripts
| Selected | Gene | Transcript | Tags | HGVSc | HGVSp | Effect | Exon Rank | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|---|
| MSH2 | ENST00000233146.7 | TSL:1 MANE Select | c.1413dupA | p.Pro472ThrfsTer4 | frameshift | Exon 9 of 16 | ENSP00000233146.2 | ||
| MSH2 | ENST00000406134.5 | TSL:1 | c.1413dupA | p.Pro472ThrfsTer4 | frameshift | Exon 9 of 16 | ENSP00000384199.1 | ||
| MSH2 | ENST00000645506.1 | c.1413dupA | p.Pro472ThrfsTer4 | frameshift | Exon 9 of 17 | ENSP00000495455.1 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 31
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Hereditary nonpolyposis colorectal neoplasms Pathogenic:1
For these reasons, this variant has been classified as Pathogenic. This premature translational stop signal has been observed in individual(s) with clinical features of Lynch syndrome (PMID: 21311894). This sequence change creates a premature translational stop signal (p.Pro472Thrfs*4) in the MSH2 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in MSH2 are known to be pathogenic (PMID: 15849733, 24362816). This variant is not present in population databases (gnomAD no frequency).
Hereditary cancer-predisposing syndrome Pathogenic:1
The c.1413dupA variant, located in coding exon 9 of the MSH2 gene, results from a duplication of A at nucleotide position 1413, causing a translational frameshift with a predicted alternate stop codon (p.P472Tfs*4). This mutation has been previously identified in two Tunisian patients with colon and rectal cancers diagnosed at 52 and 38 whose family histories met Amsterdam I criteria (Moussa SA et al. Int J Colorectal Dis. 2011 Apr;26:455-67). This mutation was also seen in a Tunisian patient with colon cancer diagnosed at age 49 with loss of MSH2/MSH6 on IHC (Ben Sghaier R et al. Fam. Cancer, 2019 07;18:343-348). This alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation.
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at